An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines
- 15 July 2009
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 28 (5) , 554-560
Abstract
Aim We sought to assess the effect of sunitinib and lapatinib applied either alone or in combination, on U87 and M059K glioma cells. Methods Both cell lines were cultured as recommended by the manufacturer. Sunitinib and lapatinib were applied, either separately or in combination, in the cultured cells after cell attachment at doses of 10nM, 100nM, 1 μM and 10 μM. To determine whether the agents affect the proliferation of glioma cells, the 3-[4,5-dimethylthiazol-2-yl]-2,5 dimethyltetrazolium bromide assay was used. Apoptosis was detected using annexin V/propidium iodide detection assay, migration assay was performed in 24-well microchemotaxis chambers. The release of MMPs into the culture medium of U87 and M059K cells was measured by zymography. Results Both agents, administered either alone or in combination, decreased cell proliferation in a dose-dependent manner 48 h after their application in both cell lines. The inhibition of their combination was statistically different than the inhibition of each agent alone. Apoptosis was increased and migration of U87 and M059K cells was inhibited either by each agent alone or their combination. MMPs levels remained unaffected by the application of both agents in U87 cells. However, MMP-9 and MMP-2 levels were decreased 48 h after treatment of M059K cells with sunitinib either alone or in combination with lapatinib. Conclusion Sunitinib and/or lapatinib appear to exhibit significant effects on proliferation, apoptosis and migration of glioma cells. When applied alone, sunitinib appears to be a more potent inhibitor than lapatinib.Keywords
This publication has 28 references indexed in Scilit:
- Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the BrainJNCI: Journal of the National Cancer Institute, 2008
- Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer TherapyClinical Cancer Research, 2008
- Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted TherapiesScience, 2007
- Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastomaNeuro-Oncology, 2007
- Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal TumorsClinical Therapeutics, 2007
- Molecularly targeted therapy for malignant gliomaCancer, 2007
- Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell GrowthClinical Cancer Research, 2005
- Effects of trastuzumab on epidermal growth factor receptor‐dependent and ‐independent human colon cancer cellsInternational Journal of Cancer, 2003
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Platelet‐derived growth factor in human gliomaGlia, 1995